AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
19/26/19	0.8950 €	+5.17%	2,43,352
18/26/18	0.8510 €	-3.30%	6,29,916
17/26/17	0.8800 €	+2.09%	1,05,830
16/26/16	0.8620 €	-2.93%	1,85,355
15/26/15	0.8880 €	-0.22%	1,16,334

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 09:25:00 19/06/2026 pm IST			5-day change	1st Jan Change
0.8950 ^EUR	+5.17%		+0.56%	-41.73%

18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib

Market Cap	6.85Cr 7.86Cr 6.34Cr 5.94Cr 11Cr 741.34Cr 11Cr 75Cr 29Cr 364.9Cr 29Cr 29Cr 1.27TCr	P/E 2025 *	-	P/E 2026 *	-
Enterprise Value	6.85Cr 7.86Cr 6.34Cr 5.94Cr 11Cr 741.34Cr 11Cr 75Cr 29Cr 364.9Cr 29Cr 29Cr 1.27TCr	EV / Sales 2025	95.4x	EV / Sales 2026 *	57.1x
Free-Float	67.54%	Yield 2025 *	-	Yield 2026 *	-

18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib
17/06	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
10/06	AB Science presents new data on Masitinib
18/05	AB Science S.A. announced that it has received $2.989368 million in funding	CI
13/05	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/05	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
29/04	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
29/04	AB Science announces successful capital increase
28/04	Air Liquide, Nexans, AB Science... stocks to watch today in Paris
28/04	AB Science Reaches Maturity Extension Deal with Lenders	MT
27/04	Vinci, Lumibird, SergeFerrari... stocks to watch tomorrow in Paris
27/04	AB Science announces major agreement with creditors

17/06	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
09/06	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
02/06	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
26/05	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
25/05	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

18/06	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
18/06	Star Warsh
18/06	AB Science obtient un nouveau brevet américain pour son masitinib
17/06	Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
10/06	Bourse : Airbus veut rebondir sur le SCAF, Legrand se renforce, le marché attend Oracle

1 day	+5.17%
1 week	+0.56%
Current month	-7.16%
1 month	-7.35%
3 months	-25.66%
6 months	-29.64%
Current year	-41.73%

1 week	0.85	0.94
1 month	0.85	1
Current year	0.85	1.61
1 year	0.85	1.73
3 years	0.77	4.66
5 years	0.77	16.68
10 years	0.77	21.75

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	11/07/2001
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/05	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
09/21/09	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/21/02	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+5.17%	+0.56%	-22.17%	-80.13%	7.86Cr
MERCK & CO., INC.	-1.36%	-4.35%	+44.03%	+3.30%	28TCr
MERCK KGAA	-0.11%	-0.26%	+20.49%	-14.40%	6.63TCr
KYOWA KIRIN CO., LTD.	+1.30%	+5.71%	+2.24%	-7.88%	823.69Cr
HALOZYME THERAPEUTICS, INC.	-0.03%	-1.37%	+29.80%	+98.29%	813.09Cr
SK BIOPHARMACEUTICALS CO., LTD.	-1.92%	-1.02%	-6.35%	+4.44%	445.07Cr
YUHAN CORPORATION	-2.69%	-1.42%	-26.97%	+36.12%	370.76Cr
BETTA PHARMACEUTICALS CO., LTD.	+8.33%	+2.08%	+0.22%	+12.14%	341.75Cr
SUPERNUS PHARMACEUTICALS, INC.	+1.84%	-0.07%	+37.48%	+32.32%	257.58Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.01%	-2.64%	+5.02%	-26.66%	192.37Cr
Average	+0.95%	-1.30%	+8.38%	+5.75%	3.8TCr
Weighted average by Cap.	-0.96%	-4.30%	+36.78%	+2.45%

	2025	2026 *
Net sales	11L 12.62L 10.19L 10L 17.89L 12Cr 17.99L 1.21Cr 46.84L 5.86Cr 47.36L 46.34L 20Cr	12L 13.76L 11.11L 10.4L 19.51L 13Cr 19.63L 1.32Cr 51.1L 6.39Cr 51.66L 50.55L 22Cr
Net income	-	-
Net Debt	-	-